Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
NCT03638128 · Amgen · PHASE3 · terminated · last registry update 2022-12-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-04Phase 3 first posted: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Denosumab Injection (NCT06154707)
- 2023-08-09Also stopped (terminated): University Hospital, Montpellier, Denosumab + NaCl (placebo) (NCT02792413)
- 2023-08-02Results posted on the registry: Massachusetts General Hospital, Teriparatide + Denosumab (NCT04026256)
- 2023-05-10Phase 3 first posted: Luye Pharma Group Ltd., Denosumab (NCT05853354)
- 2023-04-14Phase 3 first posted: Shanghai JMT-Bio Inc., Narlumosbart + Denosumab (NCT05813665)
- 2023-03-14Also stopped (withdrawn): Shenzhen People's Hospital, Denosumab Only Product (NCT05065164)
- 2023-03-08Results posted on the registry: Sandoz, GP2411 + EU-Prolia (EU-authorized Prolia®) (NCT03974100)
- 2023-02-15Results posted on the registry: University of Rochester, Denosumab (NCT03839459)
- 2022-12-28Results posted on the registry: Amgen, Denosumab (NCT02352753)
- 2022-12-28Also stopped (terminated): Amgen, Denosumab (NCT02352753)
- 2022-12-06Phase 3 first posted: Shenzhen People's Hospital, Denosumab 60 mg/ml [Prolia] + Zoledronate (NCT05638399)
- 2022-11-02Results posted on the registry: Columbia University, Denosumab (NCT01558115)
- 2022-11-02Also stopped (terminated): Columbia University, Denosumab (NCT01558115)
- 2022-10-12Results posted on the registry: Massachusetts General Hospital, Denosumab 60 MG [Prolia] + Placebo Injection (NCT03292146)
- 2022-06-15Phase 3 first posted: Lambda Therapeutic Research Ltd., Denosumab + Denosumab-Ref (NCT05419427)
- 2022-06-14Results posted on the registry: National Cancer Institute (NCI), Denosumab (NCT03382574)
- 2022-06-14Also stopped (terminated): National Cancer Institute (NCI), Denosumab (NCT03382574)
- 2022-06-06Phase 3 first posted: Enzene Biosciences Ltd., ENZ215 + Prolia (NCT05405725)
- 2022-05-27Phase 3 first posted: Alvotech Swiss AG, AVT03 + Denosumab (NCT05395091)
- 2022-04-28Phase 3 first posted: Shanghai Henlius Biotech, HLX14 + Prolia® (NCT05352516)
- 2022-04-26Phase 3 first posted: Biocon Biologics UK Ltd, Bmab 1000 + Prolia® (NCT05345691)
- 2022-04-20Phase 3 first posted: mAbxience Research S.L., MB09 (denosumab biosimilar) + EU-Prolia (NCT05338086)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision